Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI learns from 14,000 prostate scans to spot aggressive cancers

NCT ID NCT05384002

Knowledge-focused Sponsor: Fondazione del Piemonte per l'Oncologia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study created a massive, secure database of over 14,000 prostate MRI scans from men with or suspected of having prostate cancer. Researchers used this data to train artificial intelligence (AI) models to better tell apart slow-growing from aggressive cancers, predict if cancer will come back, and find where it has spread. The goal is to help doctors make more precise decisions and avoid unnecessary treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

14,000 people

The number who actually took part.

Started

Feb 2021

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who underwent MRI examination with pathological confirmation of prostate cancer (positive group) or at least 1-year follow-up to exclude presence of prostate cancer (negative group).

Ages

18 to 85 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. histological confirmed PCa or suspicion of PCa (abnormal PSA values and/or positive DRE); 2. magnetic resonance imaging examination, including at least a high-resolution axial T2-weighted imaging and axila diffusion-weighted imaging (dynamic contrast-enhanced imaging is recommended, but not mandatory); 3. age ≥ 18 years at the time of diagnosis 4. signed written informed consent form (only for prospective enrollement).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hormone-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate cancer, hereditary, 7

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer Prostate cancer aggressiveness Prostate cancer metastatic Prostate cancer recurrent

Contacts and locations

Locations

  • Fondazione del Piemonte per l'Oncologia

    Candiolo, Italy, 10060, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.